Results 291 to 300 of about 286,222 (357)

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Targeted Delivery of Personalized Cancer Vaccines Based on Antibody-Antigen Complexes. [PDF]

Vaccines (Basel)
Zhang Y, Yan L, Sun H, Zhang Z, Shen F, Sun L.   +5 more
europepmc   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines

Zitvogel L, Carrier A, Manghi P, Silva CAC, Lahmar I, Birebent R, Suissa D, Laheurte C, Schreibelt G, Lemant L, FAHRNER J, de Sousa E, Berthier F, Villemonteix J, Chevalier M, Piccinno G, Hocquet D, Lebhar I, Maeurer M, Caillat-Zucman S, Kroemer G, Derosa L, Launay O, Golden E, Bol K, De Vries IJM, Adotévi O, Segata N, Formenti S, Kobold S, Pieper D, Vital M, Santos-Peral A, Zaucha M, García-Bengoa M, Thorn-Seshold J, Stirling H, Rothenfusser S, Iebba V, Almonte A, Ajami N, White M, Sahasrabhojane P, Hoballah Y, Losh J, DePinho C, Dondossola E, Wargo J.   +47 more
europepmc   +1 more source

Updates on cancer vaccines in brain cancer: Advances in neuroblastoma, delivery systems, and emerging technologies. [PDF]

Hum Vaccin Immunother
Onohuean H, Ogunmola T, Adesiyan A, Oluwamayowa Samuel A, Oni E, Okechukwu Paul Chima U.   +5 more
europepmc   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines. [PDF]

Int J Mol Sci
Yoon J, Moon H, Jeon Y, Choe S, Yoon H.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Advances in nucleic acid-based cancer vaccines. [PDF]

J Biomed Sci
Liao HC, Liu SJ.
europepmc   +1 more source

Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update. [PDF]

Cancers (Basel)
Magoola M, Niazi SK.
europepmc   +1 more source